Leronlinab's potential to be highly effective for so many indications is a very significant threat to BP.. Deep pockets and long standing relationships will enable BP to dictate Leronlinab's fate. Short of taking the FDA to court we may never get there. A more preferred way would be to get the message somehow to a prominent, trusted, individual to advocate on LL's behalf. Bill Gates, Warren Buffert Jamie Dimon are names that come to mind. All three are non political and do not have an axe to grind.

You may say that small clinical stage bio's do win FDA .approval. That is true but with LL we are talking about the potential to put some BP's out of business. If any one indication is approved it will be open season for off label use for all of it's indications. For example Gilead is foremost in HIV, prominent in Nash, and, has an approved CV antibody. Virtually out of business over time with LL approval.